- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- CLLS
- Stock Information
- Founded
- AOMR 2018
- CLLS 1999
- Country
- AOMR United States
- CLLS France
- Employees
- AOMR N/A
- CLLS N/A
- Industry
- AOMR Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- CLLS Health Care
- Exchange
- AOMR Nasdaq
- CLLS Nasdaq
- Market Cap
- AOMR 237.8M
- CLLS 143.4M
- IPO Year
- AOMR 2021
- CLLS 2007
- Fundamental
- Price
- AOMR $9.70
- CLLS $1.58
- Analyst Decision
- AOMR Strong Buy
- CLLS Buy
- Analyst Count
- AOMR 6
- CLLS 1
- Target Price
- AOMR $11.75
- CLLS $4.00
- AVG Volume (30 Days)
- AOMR 85.4K
- CLLS 54.7K
- Earning Date
- AOMR 08-05-2025
- CLLS 08-05-2025
- Dividend Yield
- AOMR 13.20%
- CLLS N/A
- EPS Growth
- AOMR N/A
- CLLS N/A
- EPS
- AOMR 1.51
- CLLS N/A
- Revenue
- AOMR $57,147,000.00
- CLLS $54,747,000.00
- Revenue This Year
- AOMR N/A
- CLLS $48.52
- Revenue Next Year
- AOMR $10.94
- CLLS $5.17
- P/E Ratio
- AOMR $6.42
- CLLS N/A
- Revenue Growth
- AOMR N/A
- CLLS 351.26
- 52 Week Low
- AOMR $7.36
- CLLS $1.10
- 52 Week High
- AOMR $12.94
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- AOMR 66.03
- CLLS 64.58
- Support Level
- AOMR $9.11
- CLLS $1.41
- Resistance Level
- AOMR $9.35
- CLLS $1.65
- Average True Range (ATR)
- AOMR 0.15
- CLLS 0.10
- MACD
- AOMR 0.06
- CLLS 0.03
- Stochastic Oscillator
- AOMR 79.59
- CLLS 93.81
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.